Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Once-Daily LY3502970 vs Placebo and Once-Weekly Dulaglutide in Type 2 Diabetes Mellitus
2021-002806-29Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of orforglipron in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary: Change from baseline in HbA1c at Week 26 (LY3502970 vs placebo). Started Aug 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-002806-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002806-29.